Annogen Forays Research Collaboration with Orchard Therapeutics

Annogen, a biotechnology firm declared a research collaboration with Orchard Therapeutics, a worldwide gene therapy treatment pioneer, for the recognizable proof of immune cell-explicit human advertisers for use in specific pre-clinical hematopoietic stem cell (HSC) gene therapy programmes.

Utilizing its proprietary Survey of Regulatory Elements (SuRE) innovation, Annogen comprehensively examines the whole human administrative genome in vitro and in vivo to recognize DNA components that are dynamic in various cell types and conditions. Later, synergy of promoters and enhancers are monitored to find the suitable hybrid promoter to drive gene expression in a cell- or disease-specific manner.

“Building on the safe and effective human promoters we have for our existing programs, we are excited to further establish a leadership position in the field by supporting research for additional CNS-focused cellular targets,” said Frank Thomas, president and chief operating officer of Orchard Therapeutics. “This work is critical as we apply our clinically-validated HSC gene therapy platform to more prevalent diseases. We look forward to utilizing Annogen’s SuRE technology to potentially advance certain pre-clinical programmes.”

“Annogen has gained substantial experience identifying and developing promoters for in vivo gene therapy,” Joris van Arensbergen CEO of Annogen adds. “We are very pleased to work with a company in this field that has managed to bring autologous cell therapy through to commercialization in the US and Europe. We are proud to be part of their program and to contribute to the safety and efficacy of certain pre-clinical therapies.”